SYDNEY, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (Recce or the Company), the Company developing a new class of synthetic anti-infectives, today announced ...

Recce is expected to initiate a Phase III study of R327G in Australia in H1 2025 that will serve as a registrational trial for the U.S. Food and Drug Administration (FDA) and Australian ...

Recce has wrapped up dosing of patients in phase II trial of topical gel treatment for infectious skin diseases. Special Report: Recce Pharmaceuticals has wrapped up dosing of all patients in its ...

Special Report: Recce Pharmaceuticals has wrapped up dosing of all patients in its phase II clinical trial of its topical gel treatment for acute bacterial skin and skin structure infections.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Development and commercialisation of a drug discovery and development business commercialising new Classes of synthetic anti-infectives with broad spectrum activity designed to address the urgent ...

the Old Course at St Andrews is the most constant course on the Open Rota. In early January 2025, St Andrews was announced as the host venue of the 2027 Open, seemingly returning to a rotation every ...

Recce Pharmaceuticals (ASX:RCE) has dosed all 30 patients in its Phase 2 clinical trial assessing the efficacy of RECCE 327 topical gel for the treatment of acute bacterial skin and skin structure ...

Recce is expected to initiate a Phase III study of R327G in Australia in H1 2025 that will serve as a registrational trial for the U.S. Food and Drug Administration (FDA) and Australian Therapeutic ...

After hours: January 24 at 4:07:01 PM EST Loading Chart for ST ...